Showing 17,741 - 17,760 results of 45,525 for search '(( 5 ((nm decrease) OR (mean decrease)) ) OR ( 50 ((teer decrease) OR (a decrease)) ))', query time: 1.10s Refine Results
  1. 17741
  2. 17742
  3. 17743

    Severity of anaemia status among pregnant women. by Donatus Nbonibe Abaane (15909683)

    Published 2023
    “…At 36 weeks, AIP prevalence was 44.8% (95%CI:39.2, 50.4) using a cut-off of 11.0g/dl. At p<0.05, registering after the first trimester (AOR = 1.87, 95%CI: 1.17, 2.98, P = 0.009) and at a regional hospital (AOR = 2.25, 95%CI: 1.02, 4.98, P = 0.044) were associated with increased odds of AIP but registering at a private hospital (AOR = 0.32, 95%CI: 0.11, 0.92, P = 0.035) was associated with decreased odds of AIP at booking. …”
  4. 17744
  5. 17745

    Maternal Transfer of 2‑Ethylhexyl Diphenyl Phosphate Leads to Developmental Toxicity Possibly by Blocking the Retinoic Acid Receptor and Retinoic X Receptor in Japanese Medaka (Ory... by Yu Li (183836)

    Published 2021
    “…2-Ethylhexyl diphenyl phosphate (EHDPP) has been detected in wild fish with high concentrations, which may pose a risk in the embryo development considering its potential maternal transfer. …”
  6. 17746
  7. 17747

    Expected changes in obesity after reformulation to reduce added sugars in beverages: A modeling study by Ana Basto-Abreu (5823866)

    Published 2018
    “…On average, 12.6% of the TEI was contributed by added sugars; we defined a 50% reduction in added sugars in SSBs over 10 years as a reformulation target. …”
  8. 17748

    The efficacy of topical 8% capsaicin patches for the treatment of postsurgical neuropathic pain: a systematic review by Brandon Goodwin (20328988)

    Published 2024
    “…All studies that investigated neuropathic pain area denote a decrease in pain size, with some denoting a continued reduction with subsequent application.…”
  9. 17749

    Prenatal medication use in a prospective pregnancy cohort by pre-pregnancy obesity status by Yassaman Vafai (10294851)

    Published 2021
    “…A total of 17 classes of medications were identified. …”
  10. 17750

    DataSheet_1_A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in health... by Richard T. Kenney (15289313)

    Published 2024
    “…</p>Methods<p>SB102 (NCT05408572) focused on safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) endpoints. SON-1010 at 50-300 ng/kg or placebo administered subcutaneously on day 1 was studied at a ratio of 6:2, starting with two sentinels; participants were followed through day 29. …”
  11. 17751
  12. 17752

    Created with BioRender.com. by Simone Schiavo (15999287)

    Published 2024
    “…Thirteen patients had HFpEF (mean LVEF 55 ± 7%), and seven patients had HFrEF (mean LVEF 35 ± 8%) as well as concomitantly decreased right ventricle function (n = 5), moderate/severe tricuspid regurgitation (n = 3), or pulmonary hypertension (n = 5). …”
  13. 17753

    Hyperbaric oxygen therapy details. by Simone Schiavo (15999287)

    Published 2024
    “…Thirteen patients had HFpEF (mean LVEF 55 ± 7%), and seven patients had HFrEF (mean LVEF 35 ± 8%) as well as concomitantly decreased right ventricle function (n = 5), moderate/severe tricuspid regurgitation (n = 3), or pulmonary hypertension (n = 5). …”
  14. 17754

    Triple immunofluorescence labeling comparing both sarcomeric actin and VDAC expression in control versus MFN2 mutant mice. by Peter Bannerman (3373028)

    Published 2016
    “…Initially, note the selective expression of the mutant form of MFN2 in satellite cells of the mutant myofibers with occasion dissemination into the muscle fiber (white arrow-heads). Also note both the decreased intensity of sarcomeric actin immunolabelling in the mutant mice versus wild-type mice (compare A and B) and the relative disruption of striated myofibrillar distribution of VDAC positive mitochondria in mutant micrograph D versus C. …”
  15. 17755
  16. 17756
  17. 17757
  18. 17758
  19. 17759

    The impact of a CTL-based vaccine is dependent upon the extent to which it affects transmission potential. by Helen R. Fryer (194033)

    Published 2011
    “…One vaccine (circles, A and B) considerably reduces transmission probability by a factor of 25 (), but restores life expectancy to its normal value (50 years; years<sup>−1</sup>). …”
  20. 17760